Principal Financial Group Inc Pro Qr Therapeutics N.V. Transaction History

Principal Financial Group Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2018 May 14, 2018	SELL	$2.9 - $3.5 $870 - $1,050	-300 Reduced 0.41%	72,796 $224,000
Q4 2017 Feb 13, 2018	SELL	$2.8 - $4.8 $23,514 - $40,310	-8,398 Reduced 10.31%	73,096 $236,000
Q3 2017 Nov 02, 2017	BUY	$4.35 - $6.45 $354,498 - $525,636	81,494	81,494 $395,000

17.4M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $188M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.